Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma

Pediatr Blood Cancer. 2009 Dec 15;53(7):1346-8. doi: 10.1002/pbc.22255.

Abstract

Malignant melanoma is rare in pediatrics, and therapies for patients with disseminated disease have not been well studied. This report describes our experience with the use of high-dose interleukin 2 (aldesleukin, IL-2) in a 2-year-old child with metastatic melanoma and describes our approach for the administration of this agent to young patients.

Publication types

  • Case Reports

MeSH terms

  • Analgesics / administration & dosage
  • Analgesics / therapeutic use
  • Anemia / chemically induced
  • Antidiarrheals / administration & dosage
  • Antidiarrheals / therapeutic use
  • Antiemetics / administration & dosage
  • Antiemetics / therapeutic use
  • Chest Pain / chemically induced
  • Combined Modality Therapy
  • Fatal Outcome
  • Female
  • Fluid Therapy
  • Humans
  • Hypotension / chemically induced
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Infant
  • Infusions, Intravenous
  • Interferons / therapeutic use*
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / adverse effects
  • Interleukin-2 / therapeutic use*
  • Lymph Node Excision
  • Lymphatic Metastasis*
  • Melanoma / drug therapy
  • Melanoma / secondary*
  • Melanoma / surgery
  • Neoplasm Recurrence, Local / drug therapy*
  • Premedication
  • Pulmonary Edema / chemically induced
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / surgery

Substances

  • Analgesics
  • Antidiarrheals
  • Antiemetics
  • Immunologic Factors
  • Interleukin-2
  • Interferons